Regenerative Medicine Market Analysis By Product (Therapeutics {Primary Cell-based, Stem Cell-based, Immunotherapies, & Gene Therapies}, Tools, Banks, & Services), By Therapeutic Category, And Segment Forecasts, 2014 - 2025

Date: July 21, 2017
Pages: 250
Price:
US$ 5,950.00
License [?]:
Publisher: Grand View Research, Inc.
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RFB52002DB9EN
Leaflet:

Download PDF Leaflet

Regenerative Medicine Market Analysis By Product (Therapeutics {Primary Cell-based, Stem Cell-based, Immunotherapies, & Gene Therapies}, Tools, Banks, & Services), By Therapeutic Category, And Segment Forecasts, 2014 - 2025
The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. Increased prevalence of neurodegenerative, orthopedic, and other aging-related disorders in geriatric population coupled with rising global geriatric population is anticipated to drive market growth.

Developments in biotechnology have enabled gaining in-depth knowledge pertaining to cell division and differentiation as well as the metabolism mechanism of various cells. This enriched knowledge, coupled with emergence of novel streams of biotechnology such as gene therapy and nanotechnology, further prospered use of cell-based technology in therapeutic treatment.

Well established regenerative approached for various dermatological indications exists since ages. Technological advances introduced scaffolds, matrices, and grafts engineered for faster regeneration and minimal surgical procedure.

Identification of ability of stem cells to develop into various different cell lines further propelled the advancements in regenerative medicine. Frequent media exposure due to regulatory as well as ethical controversies around embryonic stem cells has increased awareness among the masses. This encouraged researchers to explore and develop other potential fields for similar applications, such as induced pluripotent stem cells (iPSC).

Furthermore, the emergence of gene therapy techniques with potential to rectify and restore effects of gene mutations in cells is under development. Conditions caused due to Single Nucleotide Polymorphism (SNP) as well as mutations that induce degenerative characteristics are primarily targeted.

Biologics, individually or in combination with cells or devices, are explored to support regenerate the biological functions of cells, tissues, or organs. A number of combinatorial therapies to support chemotherapy and other cancer treatments by prevention as well as treatment for cancer relapse are in development phases.

In addition, rising prevalence of complicated degenerative disorders such as age-related macular degeneration, Alzheimer’s disease, and Parkinson’s disease, especially in the aging population resulted in high investments in R&D to develop therapeutic solutions.

Regenerative medicine grabs the attention of the healthcare industry owing to its promising applications along with significant advances in supportive fields including tissue engineering, stem cells, gene therapy, drug discovery and nanotechnology. For instance, 3D printing over scaffold with stem cells to restore structure as well as functional characteristics of biological cells, tissues, and organs.

Further key findings from the report suggest:
  • The global regenerative medicine demand exceeded USD 1.7 billion in 2016 and is expected to grow at a considerable rate over the forecast period owing to the presence of a strong looking product pipeline with anticipated commercializations just around the corner
  • Therapeutics emerged as the largest product segment in 2016 as it has a relatively high implementation and usage rate resulting in higher adoption
  • Global regenerative services demand for facilities such as tissue banks and cellular engineering tools is expected to drive demand in the segment
  • The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies with increased focus of dominant players in emerging economies is attributive to market growth. market.
  • Key players including Asterias Bio, Athersys, Integra LifeSciences Corpotation, and MiMedx are involved in complex technical cum financial partnerships with larger players in an attempt to expedite R&D
CHAPTER 1 RESEARCH METHODOLOGY

1.1. Information Procurement
  1.1.1. Purchased Database
  1.1.2. GVR’s Internal Database
1.2. Data Analysis
1.3. Market Formulation & Validation
1.4. Approaches for Market Estimation
  1.4.1. Approach 1: Commodity Flow & Bottom Up Approach
  1.4.2. Approach 2: Top Down and Parent Market Analysis

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Snapshot

CHAPTER 3 REGENERATIVE MEDICNIE MARKET VARIABLES, TRENDS & SCOPE

3.1 Market Segmentation & Scope
  3.1.1 Market driver analysis
    3.1.1.1 Presence of strong pipeline portfolio and high number of clinical trials
      3.1.1.1.1 Major milestones & key events in regenerative medicine
    3.1.1.2 High economic impact of regenerative medicine
    3.1.1.3 Emerging applications of gene therapy in regenerative medicine
    3.1.1.4 High investment & funding to support development of RM
    3.1.1.5 Technological advances in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
    3.1.1.6 Presence of strategic partnerships to accelerate development & commercialization of regenerative medicine
    3.1.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
  3.1.2 Market restraint analysis
    3.1.2.1 High cost of treatment
    3.1.2.2 Regulatory issues pertaining stem cell, tissues engineering and regenerative medicine
    3.1.2.3 Ethical issues related to use of stem cell & regenerative medicines for R&D
3.2 Penetration & Growth Prospect Mapping for Therapeutic Category, 2016
3.3 Regenerative Medicine -SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis – Porter’s
3.5 Regenerative Medicine: Pipeline Analysis
  3.5.1 Astellas Pharma Inc.
  3.5.2 Bayer AG
  3.5.3 AstraZeneca
  3.5.4 F. Hoffmann-La Roche Ltd
  3.5.5 Pfizer Inc.
  3.5.6 Merck & Co., Inc.
  3.5.7 Abbott (St. Jude Children's Research Hospital)
  3.5.8 Vericel Corporation
  3.5.9 Novartis AG
  3.5.10 GlaxoSmithKline plc.
  3.5.11 Baxter
  3.5.12 Boehringer Ingelheim GmbH
  3.5.13 Amgen Inc.
  3.5.14 Eli Lilly and Company
  3.5.15 Bristol-Myers Squibb Company
  3.5.16 TAKARA BIO INC.
  3.5.17 Vital Therapies, Inc. (VTL)
  3.5.18 Swedish Orphan Biovitrum
  3.5.19 Stratatech Corporation
  3.5.20 Stempeutics Research Pvt. Ltd
  3.5.21 Soluble Systems, LLC
  3.5.22 Smith & Nephew plc
  3.5.23 Shire Pharmaceuticals Group PLC
  3.5.24 Beike Biotechnology Co., Ltd.
  3.5.25 SanBio, Inc.
  3.5.26 ReNeuron Group plc
  3.5.27 Regeneus Ltd.
  3.5.28 Regen BioPharma, Inc
  3.5.29 Q Therapeutics, Inc.
  3.5.30 Promethera Biosciences
  3.5.31 Pluristem Therapeutics, Inc. (PSTI)
  3.5.32 Pharmicell Co., Ltd.
  3.5.33 Osiris Therapeutics, Inc.
  3.5.34 Orthofix International NV
  3.5.35 Orthocell Limited
  3.5.36 Takeda Pharmaceutical Company Limited
  3.5.37 Caladrius
  3.5.38 U.S. Stem cell Inc.
  3.5.39 Cesca Therapeutics
  3.5.40 Osiris Therapeutics Inc.
  3.5.41 Astellas
  3.5.42 Opex Therapeutics, Inc.
  3.5.43 Northern Therapeutics, Inc.
  3.5.44 Northern Therapeutics, Inc.
  3.5.45 Neuralstem Inc.
  3.5.46 Multigene Vascular Systems, Inc.
  3.5.47 MEDIPOST Co.Ltd.
  3.5.48 Mesoblast Ltd.
  3.5.49 MacroCure, Inc.
  3.5.50 Living Cell Technologies, Ltd.
3.6 Regulatory Environment
  3.6.1 Regulatory environment: U.S.
  3.6.2 Regulatory environment: Canada
  3.6.3 Regulatory environment: Europe
  3.6.4 Regulatory environment: Japan
    3.6.4.1 Regenerative Medicine: Risk classification technique
  3.6.5 Regulatory environment: China

CHAPTER 4 REGENERATIVE MEDICINE MARKET: PRODUCT TYPE ESTIMATES & TREND ANALYSIS

4.1 Regenerative Medicine Market: Product Type Movement Analysis
4.2 Therapeutics
  4.2.1 Global regenerative medicine therapeutics market, 2014 - 2025 (USD Million)
  4.2.2 Primary cell-based therapeutics
    4.2.2.1 Global primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    4.2.2.2 Dermatology
      4.2.2.2.1 Various approaches for skin regeneration
      4.2.2.2.2 Global dermatology primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    4.2.2.3 Musculoskeletal
      4.2.2.3.1 Global musculoskeletal primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    4.2.2.4 Surgical
      4.2.2.4.1 Global surgical primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    4.2.2.5 Dental
      4.2.2.5.1 Global dental primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    4.2.2.6 Others
      4.2.2.6.1 Global other primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  4.2.3 Stem cell & progenitor cell-based therapeutics
    4.2.3.1 Global stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
    4.2.3.2 Autologous
      4.2.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
    4.2.3.3 Allogeneic
      4.2.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
    4.2.3.4 Others
      4.2.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  4.2.4 Cell-based Immunotherapies
    4.2.4.1 Global cell-based immunotherapies market, 2014 - 2025 (USD Million)
  4.2.5 Gene Therapies
    4.2.5.1 Global gene therapies market, 2014 - 2025 (USD Million)
4.3 Tools
  4.3.1 Global regenerative medicines tools market, 2014 - 2025 (USD Million)
4.4 Banks
  4.4.1 Global cell banks market, 2014 - 2025 (USD Million)
4.5 Services
  4.5.1 Global regenerative medicine services market, 2014 - 2025 (USD Million)

CHAPTER 5 REGENERATIVE MEDICINE MARKET: THERAPEUTIC CATEGORY ESTIMATES & TREND ANALYSIS

5.1 Regenerative Medicine Market: Therapeutic Category Movement Analysis
5.2 Dermatology
  5.2.1 Global dermatological therapeutics market, 2014 - 2025 (USD Million)
5.3 Musculoskeletal
  5.3.1 Global musculoskeletal therapeutics market, 2014 - 2025 (USD Million)
5.4 Immunology & Inflammation
  5.4.1 Global immunology & inflammation therapeutics market, 2014 - 2025 (USD Million)
5.5 Oncology
  5.5.1 Global oncology therapeutics market, 2014 - 2025 (USD Million)
5.6 Cardiovascular
  5.6.1 Global cardiovascular therapeutics market, 2014 - 2025 (USD Million)
5.7 Ophthalmology
  5.7.1 Global ophthalmology therapeutics market, 2014 - 2025 (USD Million)
5.8 Others
  5.8.1 Global other therapeutics market, 2014 - 2025 (USD Million)

CHAPTER 6 REGENERATIVE MEDICINE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT AND THERAPEUTIC CATEGORY

6.1 Regenerative Medicine Market Share by Region, 2016 & 2025
6.2 North America
  6.2.1 North America regenerative medicines market,by product type, 2014 - 2025 (USD Million)
  6.2.2 North America regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.2.3 U.S.
    6.2.3.1 U.S. regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.2.3.2 U.S. regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.2.4 Canada
    6.2.4.1 Canada regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.2.4.2 Canada regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
6.3 Europe
  6.3.1 Europe regenerative medicines market,by product type, 2014 - 2025 (USD Million)
  6.3.2 Europe regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.3.3 Germany
    6.3.3.1 Germany regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.3.3.2 Germany regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.3.4 UK
    6.3.4.1 UK regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.3.4.2 UK regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
6.4 Asia Pacific
  6.4.1 Asia Pacific regenerative medicines market,by product type, 2014 - 2025 (USD Million)
  6.4.2 Asia Pacific regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.4.3 Japan
    6.4.3.1 Japan regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.4.3.2 Japan regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.4.4 China
    6.4.4.1 China regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.4.4.2 China regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
6.5 Latin America
  6.5.1 Latin America regenerative medicines market,by product type, 2014 - 2025 (USD Million)
  6.5.2 Latin America regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.5.3 Brazil
    6.5.3.1 Brazil regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.5.3.2 Brazil regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
6.6 Middle East & Africa
  6.6.1 Middle East & Africa regenerative medicines market,by product type, 2014 - 2025 (USD Million)
  6.6.2 Middle East & Africa regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  6.6.3 South Africa
    6.6.3.1 South Africa regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    6.6.3.2 South Africa regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)

CHAPTER 7 COMPETITIVE LANDSCAPE

7.1 Strategy Framework
7.2 Market Participation Categorization
7.3 Company Profiles
  7.3.1 Integra LifeSciences Corporation
    7.3.1.1 Company overview
    7.3.1.2 Financial performance
    7.3.1.3 Product benchmarking
    7.3.1.4 Strategic initiatives
  7.3.2 Astellas Pharma Inc.
    7.3.2.1 Company overview
      7.3.2.1.1 Ocata Therapeutics, Inc.
    7.3.2.2 Financial performance
      7.3.2.2.1 Financial Performance
    7.3.2.3 Product benchmarking
    7.3.2.4 Strategic initiatives
  7.3.3 Corline Biomedical AB
    7.3.3.1 Company overview
    7.3.3.2 Financial performance
    7.3.3.3 Product benchmarking
    7.3.3.4 Strategic initiatives
  7.3.4 COOK BIOTECH, INC.
    7.3.4.1 Company overview
    7.3.4.2 Financial performance
    7.3.4.3 Product benchmarking
    7.3.4.4 Strategic initiatives
  7.3.5 Bayer BV
    7.3.5.1 Company overview
      7.3.5.1.1 BlueRock Therapeutics
    7.3.5.2 Financial performance
    7.3.5.3 Product benchmarking
    7.3.5.4 Strategic initiatives
  7.3.6 AstraZeneca
    7.3.6.1 Company overview
      7.3.6.1.1 MedImmune
    7.3.6.2 Financial performance
    7.3.6.3 Product benchmarking
    7.3.6.4 Strategic initiatives
  7.3.7 F. Hoffmann-La Roche Ltd
    7.3.7.1 Company overview
    7.3.7.2 Financial performance
    7.3.7.3 Product benchmarking
    7.3.7.4 Strategic initiatives
  7.3.8 Pfizer Inc.
    7.3.8.1 Company overview
    7.3.8.2 Financial performance
    7.3.8.3 Product benchmarking
    7.3.8.4 Strategic initiatives
  7.3.9 Merck & Co., Inc.
    7.3.9.1 Company overview
      7.3.9.1.1 Sigma-Aldrich Co. LLC
      7.3.9.1.2 Merck Millipore
    7.3.9.2 Financial performance
      7.3.9.2.1 Financial performance
    7.3.9.3 Product benchmarking
    7.3.9.4 Strategic initiatives
  7.3.10 Abbott
    7.3.10.1 Company overview
      7.3.10.1.1 St. Jude Medical, Inc.
    7.3.10.2 Financial performance
      7.3.10.2.1 Financial performance
    7.3.10.3 Product benchmarking
  7.3.11 Vericel Corporation
    7.3.11.1 Company overview
    7.3.11.2 Financial performance
    7.3.11.3 Product benchmarking
    7.3.11.4 Strategic initiatives
  7.3.12 Novartis AG
    7.3.12.1 Company overview
      7.3.12.1.1 Alcon
    7.3.12.2 Financial performance
    7.3.12.3 Product benchmarking
    7.3.12.4 Strategic initiatives
  7.3.13 GlaxoSmithKline plc.
    7.3.13.1 Company overview
    7.3.13.2 Financial performance
    7.3.13.3 Product benchmarking
    7.3.13.4 Strategic initiatives
  7.3.14 Baxter.
    7.3.14.1 Company overview
      7.3.14.1.1 Synovis Micro Companies Alliance Inc
    7.3.14.2 Financial performance
    7.3.14.3 Product benchmarking
  7.3.15 Boehringer Ingelheim GmbH(C.H.Boehringer Sohn AG & Co.KG, Ingelheim)
    7.3.15.1 Company overview
    7.3.15.2 Financial performance
    7.3.15.3 Product benchmarking
    7.3.15.4 Strategic initiatives
  7.3.16 Amgen Inc.
    7.3.16.1 Company overview
    7.3.16.2 Financial performance
    7.3.16.3 Product benchmarking
    7.3.16.4 Strategic initiatives
  7.3.17 Eli Lilly and Company
    7.3.17.1 Company overview
    7.3.17.2 Financial performance
    7.3.17.3 Product benchmarking
    7.3.17.4 Strategic initiatives
  7.3.18 Bristol-Myers Squibb Company
    7.3.18.1 Company overview
      7.3.18.1.1 iPierian, Inc
    7.3.18.2 Financial performance
    7.3.18.3 Product benchmarking
    7.3.18.4 Strategic initiatives
  7.3.19 Nuvasive, Inc.
    7.3.19.1 Company overview
    7.3.19.2 Financial performance
    7.3.19.3 Product benchmarking
    7.3.19.4 Strategic initiatives
  7.3.20 Organogenesis, Inc.
    7.3.20.1 Company overview
      7.3.20.1.1 NuTech
    7.3.20.2 Financial performance
      7.3.20.2.1 Financial performance
    7.3.20.3 Product benchmarking
    7.3.20.4 Strategic initiatives
  7.3.21 MiMedx Group, Inc.
    7.3.21.1 Company overview
      7.3.21.1.1 Stability, LLC.
    7.3.21.2 Financial performance
    7.3.21.3 Product benchmarking
    7.3.21.4 Strategic initiatives
  7.3.22 TAKARA BIO INC.
    7.3.22.1 Company overview
    7.3.22.2 Financial performance
    7.3.22.3 Product benchmarking
    7.3.22.4 Strategic initiatives
  7.3.23 Caladrius Biosciences, Inc.
    7.3.23.1 Company overview
    7.3.23.2 Financial performance
    7.3.23.3 Product benchmarking
    7.3.23.4 Strategic initiatives
  7.3.24 U.S. Stem Cell, Inc.
    7.3.24.1 Company overview
    7.3.24.2 Financial performance
    7.3.24.3 Product benchmarking
    7.3.24.4 Strategic initiatives
  7.3.25 Cesca Therapeutics
    7.3.25.1 Company overview
    7.3.25.2 Financial performance
    7.3.25.3 Product benchmarking
    7.3.25.4 Strategic initiatives
  7.3.26 Osiris Therapeutics, Inc
    7.3.26.1 Company overview
    7.3.26.2 Financial performance
    7.3.26.3 Product benchmarking
    7.3.26.4 Strategic initiatives


LIST OF TABLES

Table 1 U.S.: Estimated costs involved in disease area and their associated cell- and gene-based therapies
Table 2 Global landscape: Number of regenerative medicine companies including cell therapeutic companies
Table 3 2016: Clinical trials in industry by technology type
Table 4 Tax incentives for life science R&D in leading countries
Table 5 Deaths attribuTable to neurological disorders as percentage of total deaths
Table 6 Estimated prevalence and number of people with diabetes (adult 18+ years)
Table 7 Global cancer incidences, 2016
Table 8 Summary of cystic fibrosis foundation patient registry (2014 & 2015)
Table 9 Regulatory status of cell-based tissue engineering & regenerative medicine
Table 10 FDA stratification of somatic cell therapy products based on intended use and extent of manipulation
Table 11 Collaborative networks and infrastructures that support regenerative medicine in Canada
Table 12 State Food and Drug Administration (SFDA) approved stem cell products
Table 13 Stem cell research institutes in China
Table 14 SFDA approved tissue-engineering products
Table 15 Regenerative medicine used in patients
Table 16 Various approaches in regenerative medicine for dermatological use
Table 17 Various types of scaffolds in in vitro study
Table 18 Predicted prevalence of Osteoporosis and Low Bone Mass for 2010 & 2030
Table 19 Prevalence of ophthalmic diseases in U.S
Table 20 Global burden of neurological diseases: Projected number of Disability Adjusted Life Years (DALYs) for neurological disorders
Table 21 North America: Clinical studies using HCT for hematopoietic and non-hematopoietic conditions (2016)
Table 22 North America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 23 North America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 24 North America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 25 North America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 26 North America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 27 U.S. regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 28 U.S. regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 29 U.S. primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 30 U.S. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 31 U.S. regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 32 Projected economic output of Canada's stem cell industry between 2015 and 2025
Table 33 Canada regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 34 Canada regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 35 Canada primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 36 Canada stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 37 Canada regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 38 Europe regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 39 Europe regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 40 Europe primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 41 Europe stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 42 Europe regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 43 Germany regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 44 Germany regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 45 Germany primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 46 Germany stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 47 Germany regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 48 UK: National action in regenerative medicine
Table 49 UK: Funds for regenerative medicine research: 2012-2017 (in USD million)
Table 50 UK regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 51 UK regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 52 UK primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 53 UK stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 54 UK regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 55 Asia Pacific regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 56 Asia Pacific regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 57 Asia Pacific primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 58 Asia Pacific stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 59 Asia Pacific regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 60 Japan regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 61 Japan regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 62 Japan primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 63 Japan stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 64 Japan regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 65 Main monographs published in china
Table 66 China regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 67 China regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 68 China primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 69 China stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 70 China regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 71 Latin America: Current initiatives and opportunities
Table 72 Latin America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 73 Latin America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 74 Latin America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 75 Latin America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 76 Latin America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 77 Brazil regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 78 Brazil regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 79 Brazil primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 80 Brazil stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 81 Brazil regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 82 Middle East & Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 83 Middle East & Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 84 Middle East & Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 85 Middle East & Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 86 Middle East & Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
Table 87 South Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 88 South Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 89 South Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 90 South Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
Table 91 South Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)

LIST OF TABLES

Figure 1 Market research process
Figure 2 Information Procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market summary
Figure 8 Market trends & outlook
Figure 9 Market segmentation & scope
Figure 10 Market driver relevance analysis (Current & future impact)
Figure 11 Trends in clinical trials in 2014, 2015, & 2016
Figure 12 Investments in regenerative medicine in 2014, 2015, & 2016
Figure 13 Shows the data on Prevalence of chronic diseases in U.S.
Figure 14 Shows global data on deaths caused by diseases in 2015 (In Millions).
Figure 15 Market restraint relevance analysis (Current & future impact)
Figure 16 Penetration & growth prospect mapping for therapeutic category, 2016
Figure 17 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 18 Porter’s Five Forces Analysis
Figure 19 Regenerative Medicine: Risk classification technique
Figure 20 Global regenerative medicine market: Product type outlook key takeaways
Figure 21 Global regenerative medicine market: Product type movement analysis
Figure 22 Global regenerative medicine therapeutics market, 2014 - 2025 (USD Million)
Figure 23 Global primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
Figure 24 Various approaches for skin regeneration
Figure 25 Global dermatology primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
Figure 26 Global musculoskeletal primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
Figure 27 Global surgical primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
Figure 28 Global dental primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
Figure 29 Global other primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
Figure 30 Global stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
Figure 31 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
Figure 32 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
Figure 33 Global other stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
Figure 34 Global cell-based immunotherapies market, 2014 - 2025 (USD Million)
Figure 35 Global gene therapies market, 2014 - 2025 (USD Million)
Figure 36 Global regenerative medicines tools market, 2014 - 2025 (USD Million)
Figure 37 Global cell banks market, 2014 - 2025 (USD Million)
Figure 38 Global regenerative medicine services market, 2014 - 2025 (USD Million)
Figure 39 Global regenerative medicine market: Therapeutic category outlook key takeaways
Figure 40 Global regenerative medicine market: Therapeutic category movement analysis
Figure 41 Global dermatological therapeutics category market, 2014 - 2025 (USD Million)
Figure 42 Predicted prevalence of Osteoporosis and Low Bone Mass from 2010 to 2030
Figure 43 Global musculoskeletal therapeutics category market, 2014 - 2025 (USD Million)
Figure 44 Global immunology & inflammation therapeutics category market, 2014 - 2025 (USD Million)
Figure 45 Global oncology therapeutics category market, 2014 - 2025 (USD Million)
Figure 46 Global cardiovascular therapeutics category market, 2014 - 2025 (USD Million)
Figure 47 Global ophthalmology therapeutics category market, 2014 - 2025 (USD Million)
Figure 48 Global other therapeutics category market, 2014 - 2025 (USD Million)
Figure 49 Regional market place: Key takeaway
Figure 50 Regenerative medicine regional outlook, 2016 & 2025
Figure 51 North America regenerative medicines market, 2014 - 2025 (USD Million)
Figure 52 U.S regenerative medicines market, 2014 - 2025 (USD Million)
Figure 53 Canada regenerative medicines market, 2014 - 2025 (USD Million)
Figure 54 Europe regenerative medicines market, 2014 - 2025 (USD Million)
Figure 55 Germany regenerative medicines market, 2014 - 2025 (USD Million)
Figure 56 UK regenerative medicines market, 2014 - 2025 (USD Million)
Figure 57 Asia Pacific regenerative medicines market, 2014 - 2025 (USD Million)
Figure 58 Japan regenerative medicines market, 2014 - 2025 (USD Million)
Figure 59 China regenerative medicines market, 2014 - 2025 (USD Million)
Figure 60 Latin America regenerative medicines market, 2014 - 2025 (USD Million)
Figure 61 Brazil regenerative medicines market, 2014 - 2025 (USD Million)
Figure 62 Middle East & Africa regenerative medicines market, 2014 - 2025 (USD Million)
Figure 63 South Africa regenerative medicines market, 2014 - 2025 (USD Million)
Figure 64 Strategy framework
Figure 65 Participant categorization
Skip to top


Ask Your Question

Regenerative Medicine Market Analysis By Product (Therapeutics {Primary Cell-based, Stem Cell-based, Immunotherapies, & Gene Therapies}, Tools, Banks, & Services), By Therapeutic Category, And Segment Forecasts, 2014 - 2025
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: